Euro vs US Dollar

Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.

Registrieren

CRVS Corvus Pharmaceuticals Inc

4,50

-2,89 (-39,11%)

Nach Börsenschluss

Zuletzt aktualisiert: 00:38:44

Verzögert um 15 Minuten

Form EFFECT - Notice of Effectiveness

Corvus Pharmaceuticals (NASDAQ:CRVS)
Historical Stock Chart
Von Nov 2024 bis Dez 2024

Click Here for more Corvus Pharmaceuticals Charts.

Corvus Pharmaceuticals (NASDAQ:CRVS)
Historical Stock Chart
Von Dez 2023 bis Dez 2024

Click Here for more Corvus Pharmaceuticals Charts.

News Corvus Pharmaceuticals Inc

Form 8-K - Current report
Mittwoch 18 Dezember 2024 (12 Stunden vor) • Edgar (US Regulatory)

Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Mittwoch 18 Dezember 2024 (12 Stunden vor) • GlobeNewswire Inc.

Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024
Dienstag 17 Dezember 2024 (1 Tag vor) • GlobeNewswire Inc.

Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity
Mittwoch 4 Dezember 2024 (2 Wochen vor) • GlobeNewswire Inc.

Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis
Donnerstag 14 November 2024 (1 Monat vor) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Dienstag 12 November 2024 (1 Monat vor) • Edgar (US Regulatory)

Form 8-K - Current report
Dienstag 12 November 2024 (1 Monat vor) • Edgar (US Regulatory)

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results
Dienstag 12 November 2024 (1 Monat vor) • GlobeNewswire Inc.

Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer
Samstag 9 November 2024 (1 Monat vor) • GlobeNewswire Inc.

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024
Dienstag 5 November 2024 (1 Monat vor) • GlobeNewswire Inc.

Form 8-K - Current report
Mittwoch 23 Oktober 2024 (2 Monate vor) • Edgar (US Regulatory)

Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma
Dienstag 10 September 2024 (3 Monate vor) • GlobeNewswire Inc.

Weitere Corvus Pharmaceuticals Inc News-Artikel

Deutsche Lufthansa

Deutsche Telekom

Financial Select Sector

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen